Previous 10 | Next 10 |
Positive results were announced from the phase 2 NCI-led PDS0101 triple-combination study in patients with HPV16+ cancers; both CPI naive and CPI refractory patients were helped. Positive results were also announced from the phase 2 study using PDS0101 + Keytruda for recurrent or meta...
Mirum's maralixibat was approved in September. The company looks like it is executing very well. I am waiting for dips to buy back in. For further details see: Mirum Pharmaceuticals: Post-Approval Execution Looks Excellent
Today, we put Twist Bioscience in the spotlight for the first time. The stock has lost approximately two-thirds of its market value in 2022 despite posting better than expected quarterly results earlier this month. A full investment analysis follows in the paragraphs below. ...
Harmony has done very well monetizing their first asset. They have to start planning for the future. Expanding Wakix labels and acquiring new, late stage assets, are key steps. For further details see: Harmony Biosciences: Steady Revenue Generator Looking For A Future
Shares of Graphite Bio are down some 85% from their June 2021 IPO pricing, as its first-ever clinical trial for the treatment of sickle cell disease experienced a six-month delay. The company’s potentially curative technology builds on CRISPR Therapeutics by pasting a DNA templ...
In a bear market, Krystal still shows that strong execution can be lucrative. They will file a BLA this quarter. The market potential is huge. For further details see: Krystal Biotech: High Potential, Buy-At-Dips Stock
Final data from the phase 3 REGENERATE study, using Ocaliva for the treatment of patients with NASH fibrosis, is expected any day now. If all goes well with clinical data, Intercept expects a pre-submission meeting with the FDA in June of 2022. Results from the phase 3 REVERSE stu...
Aurinia and its partner OPEL expect a decision from the EMA in the 2nd half of 2022 on whether or not Lupkynis (voclosporin) will be approved for lupus nephritis in the European territories. About $21.6 million in net revenue was generated for Q1 of 2022, due to sales of Lupkynis; if ...
Shares of Greenwich LifeSciences, Inc. are trading near their lowest levels since the stock exploded upward in December 2020 in what was an illustrative example of an inefficient market. A still-pending Phase 3 study launch for its only asset in the treatment of breast cancer that was...
Novavax reported an underwhelming Q1 earnings card. Despite reiterating its FY22 guidance, the consensus estimates have been downgraded. The market is losing confidence in management's ability to deliver. Therefore, if Novavax continues to miss the estimates, we believe it could lead ...
News, Short Squeeze, Breakout and More Instantly...
ProShares UltraShort Nasdaq Biotechnology Company Name:
BIS Stock Symbol:
NASDAQ Market:
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 106.5% to $1.38 on volume of 71,739,314 shares Renalytix plc (RNLX) rose 41.4% to $0.4269 on volume of 54,892,134 shares Maxeon Solar Technologies Ltd. (MAXN) fell 7.4% to $0.1951 on volume of 45...
A look at the top 10 most actives in the United States Agrify Corporation (AGFY) rose 164.2% to $0.6658 on volume of 125,460,313 shares NVIDIA Corporation (NVDA) fell 2.9% to $122.88 on volume of 51,163,891 shares Crown Electrokinetics Corp. (CRKN) fell 0.3% to $0.04097 on volume of 44,45...